Reshetnyak VI, Maev IV. Bile acid therapy for primary biliary cholangitis: Pathogenetic validation. World J Exp Med 2025; 15(1): 101771 [DOI: 10.5493/wjem.v15.i1.101771]
Corresponding Author of This Article
Vasiliy I Reshetnyak, MD, PhD, DSc of Medicine, Professor, Department of Propaedeutics of Internal Diseases and Gastroenterology, Russian University of Medicine, No. 20 Delegatskaya Street, Build 1, Moscow 127473, Russia. vasiliy.reshetnyak@yandex.ru
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Exp Med. Mar 20, 2025; 15(1): 101771 Published online Mar 20, 2025. doi: 10.5493/wjem.v15.i1.101771
Bile acid therapy for primary biliary cholangitis: Pathogenetic validation
Vasiliy I Reshetnyak, Igor V Maev
Vasiliy I Reshetnyak, Igor V Maev, Department of Propaedeutics of Internal Diseases and Gastroenterology, Russian University of Medicine, Moscow 127473, Russia
Co-first authors: Vasiliy I Reshetnyak and Igor V Maev.
Author contributions: Reshetnyak VI and Maev IV have contributed to the study conception and design, literature review and analysis, drafting, critical revision and editing, and final approval of the final version; they contributed equally to this article, they are the co-first authors of this manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasiliy I Reshetnyak, MD, PhD, DSc of Medicine, Professor, Department of Propaedeutics of Internal Diseases and Gastroenterology, Russian University of Medicine, No. 20 Delegatskaya Street, Build 1, Moscow 127473, Russia. vasiliy.reshetnyak@yandex.ru
Received: September 25, 2024 Revised: October 25, 2024 Accepted: November 7, 2024 Published online: March 20, 2025 Processing time: 91 Days and 11.1 Hours
Core Tip
Core Tip: The review is devoted to the issues of treatment of primary biliary cholangitis (PBC) with bile acid preparations. The mechanisms of beneficial action of ursodeoxycholic acid and its derivatives (tauroursodeoxycholic acid, obeticholic acid, norursodeoxycholic acid) are considered taking into account the pathogenetic mechanisms of PBC development known so far. The assumptions about the development of new therapeutic approaches in the treatment of PBC taking into account the discovery of the disruption of the mechanisms of bicarbonate formation by cholangiocytes in PBC were outlined. This may serve as a basis for the development of new targeting drugs aimed at local reduction of microRNA 506 activity or activation of anion exchanger 2 in cholangiocytes.
